hypophosphatasia love

hypophosphatasia

Definitions

from Wiktionary, Creative Commons Attribution/Share-Alike License

  • n. A rare and sometimes fatal metabolic bone disease.

Etymologies

Sorry, no etymologies found.

Examples

  • Enobia's lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs.

    Alexion to Acquire Enobia Pharma for Up to $1.08 Billion

  • ENB-0040, an investigational treatment for hypophosphatasia, is a subcutaneous enzyme replacement therapy of tissue non-specific alkaline phosphatase (TNSALP) fused to a patented bone targeting peptide.

    RedOrbit News - Technology

  • ENB-0040, an investigational drug for the treatment of hypophosphatasia, is the Company's lead program.

    RedOrbit News - Technology

  • MONTREAL, March 29/PRNewswire/-- Enobia Pharma Inc. unveiled findings from the first hypophosphatasia (HPP) self-reported patient survey intended to evaluate the burden of illness associated with HPP at the 2010 American College of Medical Genetics (ACMG) Annual Clinical Genetics Meeting.

    RedOrbit News - Technology

  • Enobia Pharma Inc. unveiled findings from the first hypophosphatasia (HPP) self-reported patient survey intended to evaluate the burden of illness associated with HPP at the 2010

    THE MEDICAL NEWS

  • ENB-002-08 is an open-label, six month study evaluating safety, efficacy and pharmacokinetics of subcutaneous ENB-0040 in hypophosphatasia infants with severe rickets and respiratory compromise.

    Health News from Medical News Today

  • A Phase I study, which evaluated safety, tolerability and pharmacokinetics of ENB-0040 in adults with hypophosphatasia was completed in December of 2008.

    Health News from Medical News Today

  • Enzyme Replacement Therapy for the treatment of hypophosphatasia is the Company's lead program.

    Health News from Medical News Today

  • Enobia Pharma, an emerging Canadian biotech company focused on developing novel therapeutics for serious bone disorders, today announced completion of target enrollment in its pilot clinical trial in infants suffering from a severe form of hypophosphatasia.

    Health News from Medical News Today

  • MONTREAL, March 03, 2009 / PRNewswire / -- Enobia Pharma, an emerging Canadian biotech company focused on developing novel therapeutics for serious bone disorders, today announced completion of target enrollment in its pilot clinical trial in infants suffering from a severe form of hypophosphatasia.

    undefined

Comments

Log in or sign up to get involved in the conversation. It's quick and easy.